A study to investigate the safety and tolerability of BxC-I17e subcutaneous injection in patients with moderate to severe atopic dermatitis

Brief description of study

To access safety, tolerability, and preliminary efficacy of single subcutaneous (SC) dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD). The incidence of treatment-emergent adverse events (TEAEs) from baseline through Week 26 Adverse events, vital signs, physical examinations, 12-lead electrocardiograms (ECG) and laboratory parameters through Week 26.
A proportion of patients who achieved the Investigators Global Assessment (IGA) score of 0 or 1 through Week 8.
Change and percent change in Body Surface Area (BSA), Eczema Area and Severity Index (EASI) and Scoring AD (SCORAD) from baseline to each visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 852576

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).